Geeta Gulati

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

Geeta Gulati, Siri Lagethon Heck, Anne Hansen Ree et al. · European Heart Journal · 2016 · 661 citations · Full text

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol

Siri Lagethon Heck, Albulena Mecinaj, Anne Hansen Ree et al. · Circulation · 2021 · 137 citations · Full text

Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study

Geeta Gulati, Siri Lagethon Heck, Helge Røsjø et al. · Journal of the American Heart Association · 2017 · 87 citations · Full text

Heart Failure, Left Ventricular Impairment, Breast Oncology +17

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases

Sofie Gevaert, Sigrun Halvorsen, Peter Sinnaeve et al. · European Heart Journal Acute Cardiovascular Care · 2021 · 70 citations · Full text

Heart Failure, Cancer Patients, Cardiovascular Toxicity +18

Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial

Siri Lagethon Heck, Geeta Gulati, Anne Hansen Ree et al. · Cardiology · 2012 · 57 citations · Full text